显而易见性、后见之明与视角：凯斯诉泰利福案对生物技术和制药专利的影响 - Suppr

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

作者信息

Teitelbaum Rachel, Cohen Mark

机构信息

Rachel Teitelbaum and Mark Cohen are at Pearl Cohen Zedek Latzer LLP, 1500 Broadway, 12th Floor, New York, New York 10036, USA.

出版信息

Nat Biotechnol. 2007 Oct;25(10):1105-6. doi: 10.1038/nbt1007-1105.

DOI:10.1038/nbt1007-1105

PMID:17921990

Abstract

摘要

相似文献

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

Nat Biotechnol. 2007 Oct;25(10):1105-6. doi: 10.1038/nbt1007-1105.

Pharmaceutical patent life-cycle management after KSR v. Teleflex.

Food Drug Law J. 2008;63(1):275-320.

Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision.

Expert Opin Ther Pat. 2021 Oct;31(10):951-963. doi: 10.1080/13543776.2021.1931121. Epub 2021 May 26.

Biotech patents-business as usual?

Nat Biotechnol. 2008 Dec;26(12):1326. doi: 10.1038/nbt1208-1326.

Enforcing pharmaceutical and biotech patent rights in China.

Nat Biotechnol. 2008 Nov;26(11):1235-40. doi: 10.1038/nbt1108-1235.

"Ganske" threatens biotechnology patents worldwide.

Nat Biotechnol. 1997 Feb;15(2):121. doi: 10.1038/nbt0297-121a.

Supreme Court boosts licensees in biotech patent battles.

Nat Biotechnol. 2007 Mar;25(3):264-5. doi: 10.1038/nbt0307-264. Epub 2007 Mar 1.

Biotech patents: looking backward while moving forward.

Nat Biotechnol. 2006 Mar;24(3):317-9. doi: 10.1038/nbt0306-317.

Intellectual property. Drug patents at the Supreme Court.

Science. 2013 Mar 22;339(6126):1386-7. doi: 10.1126/science.1235857.

US courts narrow patent exemptions.

Nat Biotechnol. 2003 Aug;21(8):834. doi: 10.1038/nbt0803-834.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

Nat Biotechnol. 2007 Oct;25(10):1105-6. doi: 10.1038/nbt1007-1105.

Pharmaceutical patent life-cycle management after KSR v. Teleflex.

Food Drug Law J. 2008;63(1):275-320.

Avoiding hindsight in non-obviousness determination: case law review of pharmaceutical patents and guidance from the KSR v Teleflex decision.

Expert Opin Ther Pat. 2021 Oct;31(10):951-963. doi: 10.1080/13543776.2021.1931121. Epub 2021 May 26.

Biotech patents-business as usual?

Nat Biotechnol. 2008 Dec;26(12):1326. doi: 10.1038/nbt1208-1326.

Enforcing pharmaceutical and biotech patent rights in China.

Nat Biotechnol. 2008 Nov;26(11):1235-40. doi: 10.1038/nbt1108-1235.

"Ganske" threatens biotechnology patents worldwide.

Nat Biotechnol. 1997 Feb;15(2):121. doi: 10.1038/nbt0297-121a.

Supreme Court boosts licensees in biotech patent battles.

Nat Biotechnol. 2007 Mar;25(3):264-5. doi: 10.1038/nbt0307-264. Epub 2007 Mar 1.

Biotech patents: looking backward while moving forward.

Nat Biotechnol. 2006 Mar;24(3):317-9. doi: 10.1038/nbt0306-317.

Intellectual property. Drug patents at the Supreme Court.

Science. 2013 Mar 22;339(6126):1386-7. doi: 10.1126/science.1235857.

US courts narrow patent exemptions.

Nat Biotechnol. 2003 Aug;21(8):834. doi: 10.1038/nbt0803-834.

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

作者信息

Teitelbaum Rachel, Cohen Mark

机构信息

Rachel Teitelbaum and Mark Cohen are at Pearl Cohen Zedek Latzer LLP, 1500 Broadway, 12th Floor, New York, New York 10036, USA.

出版信息

Nat Biotechnol. 2007 Oct;25(10):1105-6. doi: 10.1038/nbt1007-1105.

DOI:10.1038/nbt1007-1105

PMID:17921990

Abstract

摘要

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

作者信息

机构信息

出版信息

相似文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.

作者信息

机构信息

出版信息